Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jinxing Ji

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Heliyon|July 26, 2024
With whom should I work? Partners' network characteristics and innovation persistenceJinxing Ji
Applied Biochemistry and Biotechnology|November 11, 2022
MiR-17-3p Facilitates Aggressive Cell Phenotypes in Colon Cancer by Targeting PLCD1 Through Affecting KIF14Jinxing Ji, Jun Fu
Plos One|January 25, 2024
When and how scientists influence technological performance: A moderated mediation modelJinxing Ji, Jieyu Song, Na Liu
Annals of Medicine|May 27, 2026
Mitophagy in cisplatin-induced kidney injury: regulatory mechanisms and therapeutic targetsCheng Yuan, Jinzhou Jiang, Jinxing Ji, et al.
Journal of Multidisciplinary Healthcare|May 19, 2026
Optimizing Clinical Practice and Efficacy Evaluation of Radiotherapy Combined with Immunotherapy in Recurrent Esophageal Cancer: A Retrospective Cohort Study Focusing on Patient-Reported Pain Relief and Tumor Proliferation InhibitionJinxing Ji, Lian Dong, Bojie Huang, et al.
Medicine|September 17, 2025
Network pharmacology analysis and clinical efficacy study of Fuzi Lizhong Decoction combined with XELOX plus sintilimab in the treatment of advanced gastric cancerWei Zhang, Wei Hu, Jinxing Ji, et al.
American Journal of Cancer Research|November 16, 2022
Recombinant human endostatin injection (Endostar) combined with PF chemotherapy and sequential intensity-modulated radiotherapy is tolerable and improves prognosis of locally advanced nasopharyngeal carcinoma: a randomized, open, multicenter phase II clinical studyLu Xu, Dailong Li, Jinxing Ji, et al.
Frontiers in Immunology|September 12, 2022
Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical studyDailong Li, Lu Xu, Jinxing Ji, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Heliyon|July 26, 2024
With whom should I work? Partners' network characteristics and innovation persistenceJinxing Ji
Applied Biochemistry and Biotechnology|November 11, 2022
MiR-17-3p Facilitates Aggressive Cell Phenotypes in Colon Cancer by Targeting PLCD1 Through Affecting KIF14Jinxing Ji, Jun Fu
Plos One|January 25, 2024
When and how scientists influence technological performance: A moderated mediation modelJinxing Ji, Jieyu Song, Na Liu
Annals of Medicine|May 27, 2026
Mitophagy in cisplatin-induced kidney injury: regulatory mechanisms and therapeutic targetsCheng Yuan, Jinzhou Jiang, Jinxing Ji, et al.
Journal of Multidisciplinary Healthcare|May 19, 2026
Optimizing Clinical Practice and Efficacy Evaluation of Radiotherapy Combined with Immunotherapy in Recurrent Esophageal Cancer: A Retrospective Cohort Study Focusing on Patient-Reported Pain Relief and Tumor Proliferation InhibitionJinxing Ji, Lian Dong, Bojie Huang, et al.
Medicine|September 17, 2025
Network pharmacology analysis and clinical efficacy study of Fuzi Lizhong Decoction combined with XELOX plus sintilimab in the treatment of advanced gastric cancerWei Zhang, Wei Hu, Jinxing Ji, et al.
American Journal of Cancer Research|November 16, 2022
Recombinant human endostatin injection (Endostar) combined with PF chemotherapy and sequential intensity-modulated radiotherapy is tolerable and improves prognosis of locally advanced nasopharyngeal carcinoma: a randomized, open, multicenter phase II clinical studyLu Xu, Dailong Li, Jinxing Ji, et al.
Frontiers in Immunology|September 12, 2022
Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical studyDailong Li, Lu Xu, Jinxing Ji, et al.
Pageof 1